SL

Daraxonrasib plus chemotherapy shrinks tumours in first-line metastatic pancreatic cancer

Combining the oral RAS inhibitor daraxonrasib with standard chemotherapy shrank tumours in around six in ten previously untreated patients with metastatic pancreatic cancer, according to updated phase I/II results. Median progression-free survival was 12.8 months, well beyond the five to six months typically seen wi…

sciencecatalogs.comOpens in a new tab